Home / Press Releases / The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada

The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada

DENVER, Aug. 21, 2018 (GLOBE NEWSWIRE) —

What: The International Association for the Study of Lung Cancer (IASLC) presents the IASLC 19th World Conference on Lung Cancer (WCLC) on September 23-26, 2018, in Toronto, Canada. The WCLC is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, and is expected to convene over 7,000 researchers, physicians, specialists, patients, advocates and industry members from around the world.

The WCLC’s scientific program features a line-up of global leaders in the field. Presentations focus on cutting-edge science, including the latest breakthroughs in targeted therapies and immunotherapies; advances in screening, early detection and staging; prevention and smoking cessation efforts; patient advocacy initiatives; and much more. Collaboration across disciplines and borders is a meeting highlight. The WCLC’s scientific program is available to review online.

When and Where: September 23-26, 2018, Metro Toronto Convention Centre North Building, 255 Front Street West, Toronto, Ontario, M5V 2W6, Canada

Who:  Surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates, industry representatives and media partners will gather to share findings and to further progress.

More information: Visit the conference’s official website for more information or to register.

About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contact: Becky Bunn, MSc
IASLC Public Relations Manager
Becky.Bunn@iaslc.org  | 720-325-2946

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5f8c0583-657a-48a2-9d8b-0b3bd7897a6c

Check Also

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and […]

Home / Press Releases / The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada

The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada

DENVER, Aug. 21, 2018 (GLOBE NEWSWIRE) —

What: The International Association for the Study of Lung Cancer (IASLC) presents the IASLC 19th World Conference on Lung Cancer (WCLC) on September 23-26, 2018, in Toronto, Canada. The WCLC is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, and is expected to convene over 7,000 researchers, physicians, specialists, patients, advocates and industry members from around the world.

The WCLC’s scientific program features a line-up of global leaders in the field. Presentations focus on cutting-edge science, including the latest breakthroughs in targeted therapies and immunotherapies; advances in screening, early detection and staging; prevention and smoking cessation efforts; patient advocacy initiatives; and much more. Collaboration across disciplines and borders is a meeting highlight. The WCLC’s scientific program is available to review online.

When and Where: September 23-26, 2018, Metro Toronto Convention Centre North Building, 255 Front Street West, Toronto, Ontario, M5V 2W6, Canada

Who:  Surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates, industry representatives and media partners will gather to share findings and to further progress.

More information: Visit the conference’s official website for more information or to register.

About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contact: Becky Bunn, MSc
IASLC Public Relations Manager
Becky.Bunn@iaslc.org  | 720-325-2946

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5f8c0583-657a-48a2-9d8b-0b3bd7897a6c

Check Also

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and […]